This Is MS Multiple Sclerosis Community: Knowledge & Support

Genzyme's second quarter results were published today and included the following about Campath:

Preparations are underway for the initiation of a phase 3 study of
alemtuzumab (Campath) for the treatment of relapsing/remitting multiple
sclerosis, which is expected during the second half of this year. In
addition, nearly all participating patients have now completed at least
24 months in the ongoing Phase 2 clinical trial comparing alemtuzumab
with Rebif(R) (interferon beta-1a) for the treatment of multiple
sclerosis. Genzyme expects to release data in the second half of this
year from a two-year interim analysis of this three-year study.